Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Quick links
Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101
Become a patient

Dr Kelly McGrath

MD, PhD, FRACP

  • Medical Oncologist
Become a patient Refer a patient
Wesley
07 3737 4667 07 3737 4601
drkmcgrath@icon.team

Biography

Dr Kelly McGrath believes in a compassionate and patient-centred approach to care. With a focus on open and clear communication, she helps her patients and their loved ones navigate their cancer diagnosis and personalises treatment plans to suit their individual needs.

Dr Kelly McGrath is a consultant medical oncologist at Icon Cancer Centre Wesley. She completed her Doctor of Medicine (MD) at Griffith University and undertook specialist medical oncology training in Greater Brisbane, Townsville and Sunshine Coast. In 2022 Dr McGrath became a fellow of the Royal Australasian College of Physicians (FRACP) and was appointed a medical oncology senior medical officer position at Redcliffe Hospital.

With a passion for research, multidisciplinary care and medical education, Dr McGrath has presented at local and national conferences and provides educational support to the next generation of medical professionals. Her clinical experience covers a broad range of solid tumour malignancies with a special interest in breast cancer, gastrointestinal cancer and lung cancer.

Publications

  • Conference Abstract COSA – McGrath, Chern, Kelly. A single centre retrospective chart review study of the use of geriatric assessment for older oncology patients at 2021 COSA Annual Meeting.

  • The thioredoxin system in breast cancer cell invasion and migration. M. Bhatia, K.L. McGrath, G. Di Trapani, P. Charoentong, F. Shah, M.M. King, F.M. Clarke & K.F. Tonissen. Redox Biology, 2016; 8: 68-78.

  • Conference Abstract ASCO – Mainwaring, Pyke, Korbie, Pheasant, Gascoigne, Musgrave, O’Neill, McGrath, Trau. Multi-platform quality assurance comparison of next generation sequencing technologies incorporating novel simultaneous mutation and copy number (CNV) reporting. Presented at 2015 ASCO Annual Meeting

Research

Trials being conducted by this doctor

SYMBIOTIC GI-03 / C6461003

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before.To join the study, participants must meet the following conditions:Be 18 years or older.Have colorectal cancer that has spread to other parts of your body.Be in good enough health to receive study treatment.Should not be pregnant before starting treatment.Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects.The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment.The study is expected to last approximately 33 months for each participant.Participants will have regular visits to the study site for treatment, health checks, and tests.After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects.Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.

Locations Hobart, Wesley

Diagnosis Colorectal cancer

Open for recruitment